4519 On Other Exchanges
Symbol
Exchange
4519 is not on other exchanges.

chugai pharmaceutical co ltd (4519) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan, Switzerland, and internationally. Its products for oncology include Avastin, Rituxan, Herceptin, Perjeta, Kadcyla, Xeloda, Tarceva, Neutrogin, Alecensa, Zelboraf, Aloxi, and Akynzeo; bone and joint diseases/autoimmune diseases comprise Alfarol, Edirol, Bonviva, Actemra, and Suvenyl; renal diseases consist of Mircera, Epogin, and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Pegasys, Copegus, and Sigmart. The company also has various products under development in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. The company has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

7,169 Employees
Last Reported Date: 03/24/16
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥273.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2014.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd. Announces Dividend for the Six Months Ended June 30, 2016, Payable on September 1, 2016; Provides Dividend Guidance for the Year Ending December 31, 2016

Chugai Pharmaceutical Co. Ltd. announced second quarter end dividend of JPY 26 per share for the six months ended June 30, 2016 compared to JPY 26 per share paid a year ago. Dividend will be payable on September 1, 2016. The company provided dividend guidance for the year ending December 31, 2016. The company expects year-end dividend of JPY 26 per share compared to paid dividend of JPY 32 per share a year ago.

Chugai Pharmaceutical Co. Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016; Provides Earnings Guidance for the Fiscal Year Ending December 31, 2016

Chugai Pharmaceutical Co. Ltd. announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the six months, the company reported revenues of ¥247.5 billion against ¥240.2 billion a year ago. Operating profit was ¥44.1 billion against ¥45.9 billion a year ago. Net income was ¥32.4 billion against ¥32.5 billion a year ago. On IFRS basis, revenues were ¥247.5 billion against ¥240.2 billion a year ago. Operating profit was ¥43.5 billion against ¥43.2 billion a year ago. Net income attributable to company shareholders was ¥32.0 billion or ¥57.68 diluted per share against ¥30.8 billion or ¥55.13 diluted per share a year ago. Revenues for the second quarter under review were increased of 3.0% year on year due to the strong growth in sales and increase in royalties and other operating income. Core net income was decreased of 0.3% year on year, due to the reduction of the tax burden ratio due mainly to the changes in the taxation system. Total cash flows from operating activities were ¥23.5 billion against ¥46.7 billion a year ago. Profit before taxes was ¥43.8 billion against ¥43.9 billion a year ago. Purchase of property, plant and equipment was ¥24.2 billion against ¥10.9 billion a year ago. Purchase of intangible assets was ¥3.54 billion against ¥2.88 billion a year ago. The company provided earnings guidance for the fiscal year ending December 31, 2016. For the year, the company expects revenues of ¥495,000 million, core operating profit of ¥71,000 million and core earnings per share of ¥92.54.

Chugai Pharmaceutical Co. Ltd., Q2 2016 Earnings Call, Jul 22, 2016

Chugai Pharmaceutical Co. Ltd., Q2 2016 Earnings Call, Jul 22, 2016

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4519.
View Industry Companies
 

Industry Analysis

4519

Industry Average

Valuation 4519 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.